United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

23 Jan 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, Nov 23 2016

BRIEF-Vectura's first-half pretax loss widens to 18.6 million

* H1 pretax loss -18.6 million stg versus -2.7 million stg loss year ago Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Vectura on lookout for deals to build specialized lung drug business

LONDON James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal.

Drugmaker Vectura raises revenue outlook on strong trading

Sept 7 Drugmaker Vectura Group Plc said it raised its revenue expectations for the nine months to Dec. 31 following strong trading to the end of August.

Vectura's asthma therapy misses primary endpoint in final stage trial

Aug 30 Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.

BRIEF-Vectura initiates legal proceedings against GSK in the U.S.

* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)

Select another date: